Arimidex:
- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
- First-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer
- Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with Estrogen receptor-negative (ER-negative) disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arimidex
Aromasin:
- Adjuvant treatment of postmenopausal women with estrogen-receptor positive (ER positive) early breast cancer who have received two to three years of tamoxifen and are switched to Aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy
- Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
Femara:
- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
- Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy
- First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer